相关实验视频

Updated: Sep 18, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

通过准PI3K/AKT信号通路,L-甲氨基氨基对食道癌症的进展产生抑制作用

Keyi Ji^1,2, Suhui Wu^1,3, Jiayao Yuan¹

¹Henan University of Traditional Chinese Medicine, Zhengzhou, 450046, China.

Recent patents on anti-cancer drug discovery

|June 20, 2025

概括

甲基氨基胺 (L-SeMC) 通过促进亡和抑制PI3K/AKT通路,对食道癌症表现出显著的抗癌作用. 这种化合物显示出作为食道癌治疗的新治疗策略的前景.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

食道癌是一个重大的全球健康挑战,需要开发有效的治疗干预措施.
一种化合物L-甲基氨基 (L-SeMC) 在各种癌症类型中显示出潜在的抗癌特性,但其在食道癌症中的有效性和机制需要阐明.

研究的目的:

在体外和体内研究L-甲基类固醇 (L-SeMC) 对食道癌细胞的抗癌作用.
探索L-SeMC抗食道癌活动的潜在分子机制.

主要方法:

包括MTT,殖民地形成,伤口愈合和流动细胞计在内的细胞测试被用来评估L-SeMC对细胞活力,增殖,迁移和亡的影响.
西方涂抹被用于分析与亡相关的蛋白质 (Bcl-2,Bax,caspase-3) 和PI3K/AKT信号通路的关键组件的表达.
在体内,有效性使用小鼠皮下瘤异种移植模型进行评估,分析包括TUNEL,Ki-67和HE染色.

主要成果:

根据剂量,L-SeMC显著抑制食道癌细胞的增殖,迁移和入侵.
通过调节Bcl-2和Bax表达和激活caspase-3,从而触发线粒体亡途径,L-SeMC治疗诱导了亡.
在体内研究证实了L-SeMC的抗瘤活性,并证明了其通过减少下游效应物的酸化来抑制PI3K/AKT信号通路的能力.

结论:

L-甲基类固醇 (L-SeMC) 对人类食道癌具有强大的抗癌作用.
L-SeMC促进癌细胞亡,并主要通过下调PI3K/AKT信号通路来抑制瘤生长.
L-SeMC代表了一种有前途的新型治疗候选人,用于治疗食道癌症.

关键词:

这是一种抗瘤药物.这是一种抗瘤药物.增长的增长增长的增长增长的增长.在体外和体内.状细胞癌的癌症.

更多相关视频

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...